C
Christopher N. LaRock
Researcher at Emory University
Publications - 36
Citations - 1205
Christopher N. LaRock is an academic researcher from Emory University. The author has contributed to research in topics: Inflammasome & Proinflammatory cytokine. The author has an hindex of 14, co-authored 30 publications receiving 876 citations. Previous affiliations of Christopher N. LaRock include University of Montana & University of Washington.
Papers
More filters
Journal ArticleDOI
The Yersinia virulence effector YopM binds caspase-1 to arrest inflammasome assembly and processing
TL;DR: A bacterium obstructs pyroptosis utilizing a direct mechanism of caspase-1 inhibition that is distinct from known viral or host inhibitors.
Journal ArticleDOI
The globally disseminated M1T1 clone of Group A Streptococcus evades autophagy for intracellular replication
Timothy C. Barnett,David Liebl,Lisa M. Seymour,Christine M. Gillen,Jin Yan Lim,Christopher N. LaRock,Mark R. Davies,Mark R. Davies,Benjamin L. Schulz,Victor Nizet,Rohan D. Teasdale,Mark J. Walker +11 more
TL;DR: It is found that the globally disseminated serotype M1T1 clone of GAS can evade autophagy and replicate efficiently in the cytosol of infected cells.
Journal ArticleDOI
IL-1β is an innate immune sensor of microbial proteolysis
Christopher N. LaRock,Jordan Todd,Doris L. LaRock,Joshua Olson,Anthony J. O’Donoghue,Avril A. B. Robertson,Mark E. Cooper,Hal M. Hoffman,Victor Nizet,Victor Nizet +9 more
TL;DR: It is found that GAS protease SpeB directly activates IL-1β independent of host inflammasome proteins and this may account for more frequent GAS infections in rheumatoid arthritis patients receiving anakinra, which may represent an ancestral system of innate immune regulation.
Journal ArticleDOI
Cationic antimicrobial peptide resistance mechanisms of streptococcal pathogens.
TL;DR: Recent progress in identifying the sources of CAMP resistance in the medically important Streptococcus genus is discussed, which can contribute to the understanding of streptococcal pathogenesis, and may provide new therapeutic targets for therapy and disease prevention.
Journal ArticleDOI
Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells.
Jennifer M. Dan,Jennifer M. Dan,Colin Havenar-Daughton,Colin Havenar-Daughton,Kayla Kendric,Rita Al-Kolla,Kirti Kaushik,Sandy L. Rosales,Ericka L. Anderson,Ericka L. Anderson,Christopher N. LaRock,Christopher N. LaRock,Christopher N. LaRock,Pandurangan Vijayanand,Grégory Seumois,David Layfield,Ramsey I. Cutress,Christian H. Ottensmeier,Cecilia S. Lindestam Arlehamn,Alessandro Sette,Alessandro Sette,Victor Nizet,Victor Nizet,Marcella Bothwell,Marcella Bothwell,Marcella Bothwell,Matthew T. Brigger,Matthew T. Brigger,Matthew T. Brigger,Shane Crotty,Shane Crotty,Shane Crotty +31 more
TL;DR: Results reveal that altered adaptive immune responses to group A Streptococcus may differentiate those at risk of recurrent infection, and suggest that contributors to RT susceptibility include HLA class II differences, aberrant SpeA-activated GC-TFH cells, and lower SpeA antibody titers.